Burzynski Research Institute

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Burzynski Research Institute sits in the top decile of US sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count).

52 total trials none currently recruiting 13 completed early-phase tilt top decile by trial count

Burzynski Research Institute: 52 sponsored US clinical trials, none currently recruiting.

Burzynski Research Institute sponsors 52 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 0 of these trials are in Phase 3-4 (later-stage) and 52 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glioblastoma Multiforme of the Brain, with 1 trials.

Top-decile sponsor footprint

Burzynski Research Institute ranks in the top decile of sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

13 of 52 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (25.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

52 total, page 1 of 2

TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma

NCT02988726
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Meningioma

NCT00003483
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00003498
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine

NCT00003522
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma

NCT00003513
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors

NCT00003515
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stomach Cancer

NCT00003524
COMPLETED Phase 2

Antineoplaston Therapy in Treating Children With Brain Tumors

NCT00003458
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT00003497
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

NCT00003453
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Brain Tumors

NCT00003457
COMPLETED Phase 2

Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma

NCT00003468
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma

NCT00003521
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva

NCT00003525
COMPLETED Phase 2

Antineoplaston Therapy in Treating Children With Visual Pathway Glioma

NCT00003477
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus

NCT00003487
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer

NCT00003489
TERMINATED Phase 2

Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder

NCT00003452
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma

NCT00003472
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma

NCT00003501
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer

NCT00003485
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

NCT00003492
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer

NCT00003531
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Multiple Myeloma

NCT00003511
COMPLETED Phase 2

Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors

NCT00003460
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer

NCT00003520
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer

NCT00003495
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

NCT00003516
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

NCT00003509
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer

NCT00003494
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

NCT00003491
TERMINATED Phase 2

Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer

NCT00003454
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin

NCT00003526
COMPLETED Phase 2

Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme

NCT00003474
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma

NCT00003500
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

NCT00003508
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer

NCT00003496
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

NCT00003499
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

NCT00003532
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma

NCT00003470
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas

NCT00003473
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Brain Stem Glioma

NCT00003459
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma

NCT00003471
TERMINATED Phase 2

Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors

NCT00003476
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00003533
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors

NCT00003475
TERMINATED Phase 2

Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System

NCT00003469
COMPLETED Phase 2

Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma

NCT00003537
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme

NCT00003456
TERMINATED Phase 2

Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma

NCT00003535
Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 2 52

Therapeutic Areas

Glioblastoma Multiforme of the Brain 1
Refractory Brain Tumors 1
Adult Brain Tumor 1

How the Burzynski Research Institute early-phase archive is shaped

52 indexed studies, none listed as recruiting (0% open); 13 completed (25%).

Phase mix: 0 late (III/IV) vs 52 early (I/II) (early-phase heavy).

Top condition: Glioblastoma Multiforme of the Brain (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Burzynski Research Institute: archived-pipeline peers nationwide

Peers matched on 52 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Burzynski Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0204060 0%5%10%15% Total trials Recruiting share Burzynski Research InstituteAlbany Medical CollegeDr. Reddy's Laboratories LimitedPTC TherapeuticsSpectrum Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Burzynski Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Burzynski Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 52 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Burzynski Research Institute page

52 registered trials is a research-attention snapshot, not an endorsement of Burzynski Research Institute or any single study.

  • None of Burzynski Research Institute's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Glioblastoma Multiforme of the Brain is the condition Burzynski Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glioblastoma Multiforme of the Brain trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Burzynski Research Institute pipeline card: 52 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.